Business Context and Reporting Period
Company: BillionToOne, Inc. (BLLN)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: BillionToOne is a precision diagnostics company utilizing a single-molecule next-generation sequencing (smNGS) platform for non-invasive prenatal screening (UNITY) and oncology liquid biopsy (Northstar). The company operates as a single segment focused on molecular diagnostics in the United States.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Revenue | $83,523 | $38,419 | $209,059 | $107,505 |
| Gross Profit | $58,416 | $20,215 | $139,854 | $55,196 |
| Gross Margin | 70.0% | 52.6% | 66.9% | 51.3% |
| Operating Income (Loss) | $9,633 | $(12,634) | $5,691 | $(35,454) |
| Net Income (Loss) | $5,711 | $(14,904) | $1,477 | $(30,093) |
| Net Income (Loss) Attributable to Common Stockholders | $1,507 | $(14,904) | $388 | $(30,093) |
| Cash and Cash Equivalents (End of Period) | $195,152 | $202,293 | $195,152 | $202,293 |
| Long-Term Debt | $54,986 | $51,481 | $54,986 | $51,481 |
| Operating Cash Flow (9 Months) | $13,803 | $(32,952) | $13,803 | $(32,952) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 117% year-over-year for Q3 2025 and 95% for the nine-month period. Growth was driven by a 52% increase in test volume (165,000 tests in Q3 2025 vs. 108,500 in Q3 2024) and a 44% increase in Average Selling Price (ASP).
- Profitability: The company achieved GAAP net income for the first time in the reported periods, transitioning from a net loss of $14.9 million in Q3 2024 to net income of $5.7 million in Q3 2025. Operating income improved from a loss of $12.6 million to income of $9.6 million.
- Margin Expansion: Gross margin expanded significantly to 70% in Q3 2025 from 53% in Q3 2024, attributed to higher ASPs and operational efficiencies reducing cost per test.
- Debt Structure: The company extinguished its Western Alliance Bank debt in August 2024. Current long-term debt consists of a term loan with Oberland Capital ($50 million drawn), which is accounted for at fair value, resulting in non-cash fair value adjustments impacting net income.
Guidance, Outlook, and Risks
- Subsequent Event (IPO): On November 7, 2025, the company closed its Initial Public Offering (IPO), selling 5,233,765 shares of Class A common stock at $60.00 per share. Net proceeds were approximately $286.4 million. All outstanding redeemable convertible preferred stock converted to Class A common stock.
- Outlook: Management expects continued growth driven by expanding payor coverage, increased test volumes in prenatal and oncology markets, and the rollout of new tests. The company plans to utilize cash reserves and IPO proceeds to fund operations, R&D, and facility expansion (including a new Austin, Texas facility expected to open in 2028).
- Key Risks:
- Reimbursement: Over 90% of revenue relies on third-party payors. Changes in coverage policies or reimbursement rates could materially impact revenue.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting related to the control environment, financial instrument accounting, and user access controls. Remediation is ongoing but not yet complete.
- Regulatory: Risks associated with FDA regulation of Laboratory Developed Tests (LDTs) and potential changes in enforcement discretion.
- Debt Covenants: The Oberland Capital debt agreement includes mandatory revenue and gross margin covenants. Failure to meet these could trigger default.
Investor Verification Checklist
- Reimbursement Trends: Verify the sustainability of the 44% ASP increase and the stability of payor contracts, particularly regarding Medicare and Medicaid coverage for oncology tests.
- Internal Control Remediation: Monitor the progress of remediation efforts for the identified material weaknesses in internal controls over financial reporting.
- Debt Obligations: Review the terms of the Oberland Capital note, specifically the mandatory $30 million tranche sale required by March 31, 2026, and the associated revenue/gross margin covenants.
- Non-GAAP Adjustments: Analyze the reconciliation of GAAP net income to Non-GAAP measures, noting the significant impact of fair value adjustments on the term loan and warrant liabilities.
- Capital Allocation: Assess the use of IPO proceeds ($286.4 million) against the company's burn rate and planned capital expenditures for the Austin facility.